Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with no recognized clinical prognostic factor. Creatinine kinase (CK) increase in these patients is already described with conflicting results on prognosis and survival. In 126 ALS patients who were fast or slow disease progressors, CK levels were assayed for 16 months every 4 months in an observational case-control cohort study with prospective data collection conducted in Italy. CK was also measured at baseline in 88 CIDP patients with secondary axonal damage and in two mouse strains (129SvHSD and C57-BL) carrying the same SOD1G93A transgene expression but showing a fast (129Sv-SOD1G93A) and slow (C57-SOD1G93A) ALS progression rate. Higher CK was found in ALS slow progressors compared to fast progressors in T1, T2, T3, and T4, with a correlation with Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores. Higher CK was found in spinal compared to bulbar-onset patients. Transgenic and non-transgenic C57BL mice showed higher CK levels compared to 129SvHSD strain. At baseline mean CK was higher in ALS compared to CIDP. CK can predict the disease progression, with slow progressors associated with higher levels and fast progressors to lower levels, in both ALS patients and mice. CK is higher in ALS patients compared to patients with CIDP with secondary axonal damage; the higher levels of CK in slow progressors patients, but also in C57BL transgenic and non-transgenic mice designs CK as a predisposing factor for disease rate progression.

Creatine kinase and progression rate in amyotrophic lateral sclerosis / Ceccanti, Marco; Pozzilli, Valeria; Cambieri, Chiara; Libonati, Laura; Onesti, Emanuela; Frasca, Vittorio; Fiorini, Ilenia; Petrucci, Antonio; Garibaldi, Matteo; Palma, Eleonora; Bendotti, Caterina; Fabbrizio, Paola; Chiara Trolese, Maria; Nardo, Giovanni; Inghilleri, Maurizio. - In: CELLS. - ISSN 2073-4409. - 9:(2020), pp. 1-12. [10.3390/cells9051174]

Creatine kinase and progression rate in amyotrophic lateral sclerosis

Marco Ceccanti;Valeria Pozzilli;Chiara Cambieri;Laura Libonati;Emanuela Onesti;Vittorio Frasca;Ilenia Fiorini;Antonio Petrucci;Matteo Garibaldi;Eleonora Palma;Maurizio Inghilleri
2020

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with no recognized clinical prognostic factor. Creatinine kinase (CK) increase in these patients is already described with conflicting results on prognosis and survival. In 126 ALS patients who were fast or slow disease progressors, CK levels were assayed for 16 months every 4 months in an observational case-control cohort study with prospective data collection conducted in Italy. CK was also measured at baseline in 88 CIDP patients with secondary axonal damage and in two mouse strains (129SvHSD and C57-BL) carrying the same SOD1G93A transgene expression but showing a fast (129Sv-SOD1G93A) and slow (C57-SOD1G93A) ALS progression rate. Higher CK was found in ALS slow progressors compared to fast progressors in T1, T2, T3, and T4, with a correlation with Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores. Higher CK was found in spinal compared to bulbar-onset patients. Transgenic and non-transgenic C57BL mice showed higher CK levels compared to 129SvHSD strain. At baseline mean CK was higher in ALS compared to CIDP. CK can predict the disease progression, with slow progressors associated with higher levels and fast progressors to lower levels, in both ALS patients and mice. CK is higher in ALS patients compared to patients with CIDP with secondary axonal damage; the higher levels of CK in slow progressors patients, but also in C57BL transgenic and non-transgenic mice designs CK as a predisposing factor for disease rate progression.
prognosis; amyotrophic lateral sclerosis; chronic inflammatory demyelinating polyneuropathy; CK; creatine kinase; neurodegenerative disease
01 Pubblicazione su rivista::01a Articolo in rivista
Creatine kinase and progression rate in amyotrophic lateral sclerosis / Ceccanti, Marco; Pozzilli, Valeria; Cambieri, Chiara; Libonati, Laura; Onesti, Emanuela; Frasca, Vittorio; Fiorini, Ilenia; Petrucci, Antonio; Garibaldi, Matteo; Palma, Eleonora; Bendotti, Caterina; Fabbrizio, Paola; Chiara Trolese, Maria; Nardo, Giovanni; Inghilleri, Maurizio. - In: CELLS. - ISSN 2073-4409. - 9:(2020), pp. 1-12. [10.3390/cells9051174]
File allegati a questo prodotto
File Dimensione Formato  
Ceccanti_Creatine-kinase_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 880.04 kB
Formato Adobe PDF
880.04 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1392645
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact